Palifermin for the reduction of acute GVHD

A randomized, double-blind, placebo-controlled trial

M. H. Jagasia, Rafat Abonour, G. D. Long, B. J. Bolwell, G. G. Laport, T. B. Shore, S. Durrant, J. Szer, M. G. Chen, R. Lizambri, E. K. Waller

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

This prospective, randomized, double-blind, placebo-controlled study evaluated the efficacy of palifermin to reduce the incidence of severe (grade 3-4) acute GVHD after myeloablation and allo-SCT. Adults who received allo-SCT for hematologic malignancies received placebo or palifermin 60 μg/kg daily on three consecutive days before conditioning and a single dose of 180 μg/kg after conditioning, but often 1 or 2 days before allo-SCT. Subjects received MTX (plus CYA or tacrolimus) on days 1, 3, 6 and 11. Acute GVHD was evaluated once weekly and oral mucositis was evaluated daily. Subjects were randomly assigned to placebo (n=78) or palifermin (n=77). Conditioning included TBI in approximately half of the subjects (48% placebo, 51% palifermin). The primary efficacy end point, subject incidence of grade 3-4 acute GVHD, was similar between treatment groups (17% placebo, 16% palifermin). Grade 3-4 oral mucositis (73% placebo, 81% palifermin) and other secondary efficacy end points were similar between treatment groups. The most commonly reported treatment-related adverse events were skin/s.c. events such as rash, pruritus, and erythema. This exploratory study of acute GVHD after myeloablation and allo-SCT did not provide evidence of a treatment effect with this dosing regimen of palifermin.

Original languageEnglish
Pages (from-to)1350-1355
Number of pages6
JournalBone Marrow Transplantation
Volume47
Issue number10
DOIs
StatePublished - Oct 2012

Fingerprint

Fibroblast Growth Factor 7
Placebos
Stomatitis
Incidence
Tacrolimus
Hematologic Neoplasms
Therapeutics
Erythema
Pruritus
Exanthema
Skin

Keywords

  • GVHD
  • Hematopoietic cell transplantation
  • MTX
  • Palifermin

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Jagasia, M. H., Abonour, R., Long, G. D., Bolwell, B. J., Laport, G. G., Shore, T. B., ... Waller, E. K. (2012). Palifermin for the reduction of acute GVHD: A randomized, double-blind, placebo-controlled trial. Bone Marrow Transplantation, 47(10), 1350-1355. https://doi.org/10.1038/bmt.2011.261

Palifermin for the reduction of acute GVHD : A randomized, double-blind, placebo-controlled trial. / Jagasia, M. H.; Abonour, Rafat; Long, G. D.; Bolwell, B. J.; Laport, G. G.; Shore, T. B.; Durrant, S.; Szer, J.; Chen, M. G.; Lizambri, R.; Waller, E. K.

In: Bone Marrow Transplantation, Vol. 47, No. 10, 10.2012, p. 1350-1355.

Research output: Contribution to journalArticle

Jagasia, MH, Abonour, R, Long, GD, Bolwell, BJ, Laport, GG, Shore, TB, Durrant, S, Szer, J, Chen, MG, Lizambri, R & Waller, EK 2012, 'Palifermin for the reduction of acute GVHD: A randomized, double-blind, placebo-controlled trial', Bone Marrow Transplantation, vol. 47, no. 10, pp. 1350-1355. https://doi.org/10.1038/bmt.2011.261
Jagasia, M. H. ; Abonour, Rafat ; Long, G. D. ; Bolwell, B. J. ; Laport, G. G. ; Shore, T. B. ; Durrant, S. ; Szer, J. ; Chen, M. G. ; Lizambri, R. ; Waller, E. K. / Palifermin for the reduction of acute GVHD : A randomized, double-blind, placebo-controlled trial. In: Bone Marrow Transplantation. 2012 ; Vol. 47, No. 10. pp. 1350-1355.
@article{1636820e665648968beb59361f4d3361,
title = "Palifermin for the reduction of acute GVHD: A randomized, double-blind, placebo-controlled trial",
abstract = "This prospective, randomized, double-blind, placebo-controlled study evaluated the efficacy of palifermin to reduce the incidence of severe (grade 3-4) acute GVHD after myeloablation and allo-SCT. Adults who received allo-SCT for hematologic malignancies received placebo or palifermin 60 μg/kg daily on three consecutive days before conditioning and a single dose of 180 μg/kg after conditioning, but often 1 or 2 days before allo-SCT. Subjects received MTX (plus CYA or tacrolimus) on days 1, 3, 6 and 11. Acute GVHD was evaluated once weekly and oral mucositis was evaluated daily. Subjects were randomly assigned to placebo (n=78) or palifermin (n=77). Conditioning included TBI in approximately half of the subjects (48{\%} placebo, 51{\%} palifermin). The primary efficacy end point, subject incidence of grade 3-4 acute GVHD, was similar between treatment groups (17{\%} placebo, 16{\%} palifermin). Grade 3-4 oral mucositis (73{\%} placebo, 81{\%} palifermin) and other secondary efficacy end points were similar between treatment groups. The most commonly reported treatment-related adverse events were skin/s.c. events such as rash, pruritus, and erythema. This exploratory study of acute GVHD after myeloablation and allo-SCT did not provide evidence of a treatment effect with this dosing regimen of palifermin.",
keywords = "GVHD, Hematopoietic cell transplantation, MTX, Palifermin",
author = "Jagasia, {M. H.} and Rafat Abonour and Long, {G. D.} and Bolwell, {B. J.} and Laport, {G. G.} and Shore, {T. B.} and S. Durrant and J. Szer and Chen, {M. G.} and R. Lizambri and Waller, {E. K.}",
year = "2012",
month = "10",
doi = "10.1038/bmt.2011.261",
language = "English",
volume = "47",
pages = "1350--1355",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "10",

}

TY - JOUR

T1 - Palifermin for the reduction of acute GVHD

T2 - A randomized, double-blind, placebo-controlled trial

AU - Jagasia, M. H.

AU - Abonour, Rafat

AU - Long, G. D.

AU - Bolwell, B. J.

AU - Laport, G. G.

AU - Shore, T. B.

AU - Durrant, S.

AU - Szer, J.

AU - Chen, M. G.

AU - Lizambri, R.

AU - Waller, E. K.

PY - 2012/10

Y1 - 2012/10

N2 - This prospective, randomized, double-blind, placebo-controlled study evaluated the efficacy of palifermin to reduce the incidence of severe (grade 3-4) acute GVHD after myeloablation and allo-SCT. Adults who received allo-SCT for hematologic malignancies received placebo or palifermin 60 μg/kg daily on three consecutive days before conditioning and a single dose of 180 μg/kg after conditioning, but often 1 or 2 days before allo-SCT. Subjects received MTX (plus CYA or tacrolimus) on days 1, 3, 6 and 11. Acute GVHD was evaluated once weekly and oral mucositis was evaluated daily. Subjects were randomly assigned to placebo (n=78) or palifermin (n=77). Conditioning included TBI in approximately half of the subjects (48% placebo, 51% palifermin). The primary efficacy end point, subject incidence of grade 3-4 acute GVHD, was similar between treatment groups (17% placebo, 16% palifermin). Grade 3-4 oral mucositis (73% placebo, 81% palifermin) and other secondary efficacy end points were similar between treatment groups. The most commonly reported treatment-related adverse events were skin/s.c. events such as rash, pruritus, and erythema. This exploratory study of acute GVHD after myeloablation and allo-SCT did not provide evidence of a treatment effect with this dosing regimen of palifermin.

AB - This prospective, randomized, double-blind, placebo-controlled study evaluated the efficacy of palifermin to reduce the incidence of severe (grade 3-4) acute GVHD after myeloablation and allo-SCT. Adults who received allo-SCT for hematologic malignancies received placebo or palifermin 60 μg/kg daily on three consecutive days before conditioning and a single dose of 180 μg/kg after conditioning, but often 1 or 2 days before allo-SCT. Subjects received MTX (plus CYA or tacrolimus) on days 1, 3, 6 and 11. Acute GVHD was evaluated once weekly and oral mucositis was evaluated daily. Subjects were randomly assigned to placebo (n=78) or palifermin (n=77). Conditioning included TBI in approximately half of the subjects (48% placebo, 51% palifermin). The primary efficacy end point, subject incidence of grade 3-4 acute GVHD, was similar between treatment groups (17% placebo, 16% palifermin). Grade 3-4 oral mucositis (73% placebo, 81% palifermin) and other secondary efficacy end points were similar between treatment groups. The most commonly reported treatment-related adverse events were skin/s.c. events such as rash, pruritus, and erythema. This exploratory study of acute GVHD after myeloablation and allo-SCT did not provide evidence of a treatment effect with this dosing regimen of palifermin.

KW - GVHD

KW - Hematopoietic cell transplantation

KW - MTX

KW - Palifermin

UR - http://www.scopus.com/inward/record.url?scp=84867402278&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867402278&partnerID=8YFLogxK

U2 - 10.1038/bmt.2011.261

DO - 10.1038/bmt.2011.261

M3 - Article

VL - 47

SP - 1350

EP - 1355

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 10

ER -